Boston, MA -- (SBWIRE) -- 09/23/2013 -- Global Markets Direct's, 'Rheumatoid Arthritis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Rheumatoid Arthritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Rheumatoid Arthritis. Rheumatoid Arthritis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

View Full Report Details and Table of Contents

Scope

- A snapshot of the global therapeutic scenario for Rheumatoid Arthritis.
- A review of the Rheumatoid Arthritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Rheumatoid Arthritis pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to Get This Report

- Identify and understand important and diverse types of therapeutics under development for Rheumatoid Arthritis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Rheumatoid Arthritis pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Companies Mentioned in this Report: Alcon, Inc., Bristol-Myers Squibb Company, Johnson & Johnson, Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd., Biogen Idec Inc., Amgen Inc., Antares Pharma, Inc., AstraZeneca PLC, Eli Lilly and Company, GlaxoSmithKline plc, Inovio Biomedical Corporation, MedImmune LLC, Isis Pharmaceuticals, Inc., Biotest AG, Merck & Co., Inc., Santen Pharmaceutical Co., Ltd., Ablynx, Emergent BioSolutions Inc., Novo Nordisk A/S, Infinity Pharmaceuticals, Inc., Albany Molecular Research, Inc., Plexxikon Inc., ViaCord, arGentis Pharmaceuticals, LLC, Reliance Life Sciences Pvt. Ltd., MediGene AG, Celltrion, Inc., Nycomed International Management GmbH, TiGenix NV, Pacira Pharmaceuticals, Inc., Samyang Corporation, Astellas Pharma Inc., Biocon Limited, Cephalon, Inc., Chugai Pharmaceutical Co. Ltd, Cipla Ltd., Daewoong Pharmaceutical Co., Ltd., Gedeon Richter Plc., Glenmark Pharmaceuticals Ltd., Kissei Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Pfizer Inc., Santarus, Inc., Toyama Chemical Co. Ltd, UCB Group, Vertex Pharmaceuticals Incorporated, Zydus Cadila Healthcare Limited, Cell Therapeutics, Inc., Genmab A/S, Hadasit Medical Research Services & Development Ltd, Sandoz Inc., Paratek Pharmaceuticals, Inc., CEL-SCI Corporation, Celgene Corporation, Onyx Pharmaceuticals, Inc., Incyte Corporation, XTL Biopharmaceuticals Ltd., Merck KGaA, Bone Medical Limited, Access Pharmaceuticals, Inc., 4SC AG, 3SBio Inc., Addex Pharmaceuticals, EntreMed, Inc., Hollis-Eden Pharmaceuticals, Inc., IMMUNOMEDICS, INC, Can-Fite BioPharma Ltd., Idera Pharmaceuticals, Inc., Karo Bio, Ligand Pharmaceuticals Incorporated, Almirall, S.A., Lupin Limited, Medivir AB, Mesoblast Ltd, PROLOR Biotech, Inc., Nutra Pharma Corporation, Compugen Ltd., Lexicon Pharmaceuticals, Inc., Arena Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., Portola Pharmaceuticals, Inc., Chelsea Therapeutics, Inc., Yuhan Corporation, KOLON LIFE SCIENCE INC., Zenotech Laboratories Limited, Regeneron Pharmaceuticals, Inc., Pharmacyclics, Inc., Protalix BioTherapeutics, Inc., Tolerx, Inc., MorphoSys AG, Dongwha Pharm Co., Ltd., Boryung Pharmaceutical Co., Ltd., Green Cross Corporation, Hanall Pharmaceutical Co., Ltd., Cytos Biotechnology AG, LG Life Sciences, Ltd, AnGes MG, Inc., Biotie Therapies Corp., Transition Therapeutics Inc., Galapagos NV, Synta Pharmaceuticals Corp., Panacea Biotec Limited, CrystalGenomics, Inc., Sareum Holdings plc, Protalex, Inc., Proximagen Neuroscience plc., Newron Pharmaceuticals S.p.A., DiaMedica Inc., Morphotek, Inc., Spectrum Pharmaceuticals, Inc., Advinus Therapeutics Pvt. Ltd., Auspex Pharmaceuticals, SCYNEXIS, Inc., Affimed Therapeutics AG, Chipscreen Biosciences Ltd, AcurePharma AB, Ambit Biosciences Corporation, Viron Therapeutics, Inc., Immupharma Plc, Palau Pharma S.A, Philogen S.p.A., Probiodrug AG, Farmacija d.o.o. Tuzla, Pharmagenesis, Inc., Acceleron Pharma, Inc., Phenex Pharmaceuticals AG, Neovacs SA, MIKA Pharma GmbH, Hutchison MediPharma Limited, CREABILIS Therapeutics S.r.l., Artielle ImmunoTherapeutics, Inc., BioNumerik Pharmaceuticals, Inc., InCode BioPharmaceutics, Inc., Aegera Therapeutics Inc., Amura Holdings Ltd., JADO Technologies GmbH., Alder Biopharmaceuticals Inc., IMMD Inc., Circassia Holdings Ltd., Coronado Biosciences, Inc., MacroGenics, Inc., Catabasis Pharmaceuticals, Inc., Antyra, Inc., Recoly N.V., Regado Biosciences., Opsona Therapeutics Ltd., Asahi Kasei Pharma, Five Prime Therapeutics, Inc., Vaccinex, Inc., Syntrix Biosystems, Inc., Alloksys Life Sciences BV, MSM Protein Technologies, Inc., Vascular Biogenics Ltd., Indus Biotech Private Limited, Xention Limited, Txcell SA, Endocyte, Inc., Theraclone Sciences, Inc., TcL Pharma SAS, Versartis, Inc., Cardax Pharmaceuticals, Inc., Inimex Pharmaceuticals, Inc., Logical Therapeutics, Inc., Omeros Corporation, Xencor, Inc., Cornerstone Therapeutics Inc., Acetylon Pharmaceuticals, Inc., Trillium Therapeutics Inc., BaroFold, Inc., Cellceutix Corporation, VentiRx Pharmaceuticals, Inc., Provid Pharmaceuticals, Inc., Resolvyx Pharmaceuticals, Inc, Biokine Therapeutics Ltd., OncoImmune, Inc., Medistem, Inc., Avesthagen Limited, KAHR medical Ltd., SuppreMol GmbH, Viromed Co., Ltd., Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Aphoenix, Inc., Covagen AG, Domainex Ltd., Dynamix Pharmaceuticals Ltd., Amplimmune, Inc., Lycera Corp., Perseid Therapeutics LLC, Sinil Pharma Ltd., OHR Pharmaceutical Inc., ImmunoFrontier, Inc., Femta Pharmaceuticals, Inc., ModiQuest B.V., Mycenax Biotech Inc., Bio Sidus S.A., Cellmid Ltd, Mebiopharm Co., Ltd., ToleroTech Inc., CellAct Pharma GmbH, Diurnal Ltd

About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- Arthritis - Pipeline Review, H2 2013
- Rheumatoid Arthritis - Pipeline Review, H1 2013
- Gouty Arthritis (Gout) - Pipeline Review, H2 2013
- Systemic Juvenile Idiopathic Arthritis (SJIA) - Pipeline Review, H2 2013
- Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H2 2013
- Alzheimer's Disease - Pipeline Review, H2 2013
- Influenza - Pipeline Review, H2 2013
- Asthma - Pipeline Review, H2 2013
- Prostate Cancer - Pipeline Review, H2 2013
- Stroke - Pipeline Review, H2 2013